0.4007USD-26.21%Mkt Cap: 725350 USDP/E: —Last update: 2026-06-01
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap725.35K USD
Enterprise Value2.77M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-5.53M USD
Revenue/Share—
Last Price0.4007 USD
Fiscal Year End—
MR QuarterDec 2025
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.94
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.44
EPS (TTM)-13.13
EPS (Forward)-0.58
52W Range
0.25003% of range6.200
52W High6.200 USD
52W Low0.2500 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-545.36%
ROA-282.49%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.22M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt1.78M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio—
Quick Ratio—
Book Value/Sh-1.2370 USD
Cash/Share1.222 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 27, 2016
Splits
Last Split1:14
Split DateMay 5, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.1.81M
Float—
Insiders3.84%
Institutions4.64%
Short Interest
Short Ratio0.6d
Short % Float3.30%
Short % Out.3.19%
Shares Short61.71K
Short (prev mo.)56.97K
Technical
SMA 500.6500 (-38.4%)
SMA 2001.624 (-75.3%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)7.50K
Avg Vol (10d)1.73K
Technical Indicators
RSI (14)45.1
MACD-0.0321
MACD Signal-0.0169
MACD Hist.-0.0152
BB Upper0.8459 USD
BB Middle0.6249 USD
BB Lower0.4038 USD
BB Width70.75%
ATR (14)0.1130 USD
Vol Ratio (20d)0.44x